These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23485609)

  • 1. Extended-release carbidopa-levodopa in Parkinson's disease.
    Rascol O
    Lancet Neurol; 2013 Apr; 12(4):325-6. PubMed ID: 23485609
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
    Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
    Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
    Bermejo Pareja F; Martínez-Martín P
    Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S;
    Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
    Lambarth AT
    CNS Drugs; 2016 Oct; 30(10):1007-8. PubMed ID: 27541607
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease.
    Busk K; Nyholm D
    Parkinsonism Relat Disord; 2012 Sep; 18(8):1000-1. PubMed ID: 22546333
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 11. Authors' Reply to Lambarth: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 Oct; 30(10):1009-10. PubMed ID: 27541606
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
    Guthikonda LN; Lyons KE; Pahwa R
    J Comp Eff Res; 2014 Jul; 3(4):331-3. PubMed ID: 25275230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
    Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
    J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
    Hutton JT; Morris JL
    Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage.
    Munro Neville A; Parsons RW; Askmark H; Nyholm D
    Parkinsonism Relat Disord; 2012 Jun; 18(5):686-7. PubMed ID: 22197121
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial.
    Gilligan B; Wodak J; Stark R; O'Halloran M
    Med J Aust; 1979 Aug; 2(4):205-7. PubMed ID: 390336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Catalan MJ; Molina-Arjona JA; Mir P; Cubo E; Arbelo JM; Martinez-Martin P;
    J Neurol; 2018 Jun; 265(6):1279-1287. PubMed ID: 29557989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.
    Salomone G; Marano M; di Biase L; Melgari JM; Di Lazzaro V
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1124-5. PubMed ID: 26242552
    [No Abstract]   [Full Text] [Related]  

  • 20. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.